Diabetic Macular Edema - Pipeline Review, H1 2015

Published: Jan, 2015 | Pages: 177 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Diabetic Macular Edema - Pipeline Review, H1 2015

Summary

Global Markets Direct's, 'Diabetic Macular Edema - Pipeline Review, H1 2015', provides an overview of the Diabetic Macular Edema's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Diabetic Macular Edema, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Diabetic Macular Edema and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Diabetic Macular Edema
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Diabetic Macular Edema and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Diabetic Macular Edema products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Diabetic Macular Edema pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Diabetic Macular Edema
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Diabetic Macular Edema pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Diabetic Macular Edema Overview 8
Therapeutics Development 9
Pipeline Products for Diabetic Macular Edema - Overview 9
Pipeline Products for Diabetic Macular Edema - Comparative Analysis 10
Diabetic Macular Edema - Therapeutics under Development by Companies 11
Diabetic Macular Edema - Therapeutics under Investigation by Universities/Institutes 15
Diabetic Macular Edema - Pipeline Products Glance 16
Late Stage Products 16
Clinical Stage Products 17
Early Stage Products 18
Unknown Stage Products 19
Diabetic Macular Edema - Products under Development by Companies 20
Diabetic Macular Edema - Products under Investigation by Universities/Institutes 23
Diabetic Macular Edema - Companies Involved in Therapeutics Development 24
ActiveSite Pharmaceuticals, Inc. 24
Acucela Inc. 25
Aerpio Therapeutics, Inc. 26
Alcon, Inc. 27
Allergan, Inc. 28
AlphaMab Co., Ltd 29
Ampio Pharmaceuticals, Inc. 30
Astellas Pharma Inc. 31
Auven Therapeutics Management L.L.L.P 32
Avalanche Biotechnologies, Inc. 33
Eleven Biotherapeutics Inc. 34
F. Hoffmann-La Roche Ltd. 35
Foamix Pharmaceuticals Ltd. 36
Gene Signal International SA 37
Genmab A/S 38
GlaxoSmithKline plc 39
Icon Bioscience, Inc. 40
Kala Pharmaceuticals, Inc. 41
Kowa Company, Ltd. 42
Mabion SA 43
MacuCLEAR, Inc. 44
Molecular Design International, Inc. 45
NicOx S.A. 46
Ohr Pharmaceutical Inc. 47
Pfizer Inc. 48
Quark Pharmaceuticals, Inc. 49
Regeneron Pharmaceuticals, Inc. 50
Santen Pharmaceutical Co., Ltd. 51
SciFluor Life Sciences, LLC 52
Senju Pharmaceutical Co., Ltd. 53
ThromboGenics NV 54
Diabetic Macular Edema - Therapeutics Assessment 55
Assessment by Monotherapy Products 55
Assessment by Target 56
Assessment by Mechanism of Action 58
Assessment by Route of Administration 60
Assessment by Molecule Type 62
Drug Profiles 64
49-B - Drug Profile 64
abicipar pegol - Drug Profile 66
aganirsen - Drug Profile 68
AKB-9778 - Drug Profile 70
ALG-1001 - Drug Profile 72
Antibodies to Inhibit Hemopexin for Diabetic Macular Edema - Drug Profile 74
ASP-440 - Drug Profile 75
ASP-8232 - Drug Profile 77
AVA-101 - Drug Profile 78
conbercept - Drug Profile 80
danazol - Drug Profile 82
darapladib - Drug Profile 83
dexamethasone acetate nanoparticle - Drug Profile 85
dexamethasone dipropionate - Drug Profile 87
difluprednate - Drug Profile 88
Drug for Diabetic Macular Edema - Drug Profile 89
Drugs to Inhibit Tyrosine Kinase for Ophthalmology - Drug Profile 90
EBI-029 - Drug Profile 91
EBI-031 - Drug Profile 92
emixustat hydrochloride - Drug Profile 93
KVD-001 - Drug Profile 95
LKA-651 - Drug Profile 96
loteprednol etabonate - Drug Profile 97
MC-4001 - Drug Profile 98
minocycline Gel - Drug Profile 99
MTP-131 - Drug Profile 100
NCX-422 - Drug Profile 102
NCX-434 - Drug Profile 103
nesvacumab - Drug Profile 104
ocriplasmin (recombinant) - Drug Profile 106
Peptide for Diabetic Macular Edema - Drug Profile 109
PF-04634817 - Drug Profile 110
PF-655 - Drug Profile 111
ranibizumab - Drug Profile 113
ranibizumab biosimilar - Drug Profile 116
ranibizumab biosimilar - Drug Profile 117
ripasudil - Drug Profile 118
RX-10045 - Drug Profile 119
SF-0166 - Drug Profile 121
Small Molecule to Inhibit Kallikrein for AMD and DME - Drug Profile 122
Small Molecules to Inhibit Plasma Kallikrein for DME and HAE - Drug Profile 123
Small Molecules to Inhibit VAP-1 for Diabetic Macular Edema - Drug Profile 125
squalamine lactate - Drug Profile 126
teprotumumab - Drug Profile 129
Diabetic Macular Edema - Recent Pipeline Updates 132
Diabetic Macular Edema - Dormant Projects 162
Diabetic Macular Edema - Discontinued Products 164
Diabetic Macular Edema - Product Development Milestones 165
Featured News & Press Releases 165
Appendix 173
Methodology 173
Coverage 173
Secondary Research 173
Primary Research 173
Expert Panel Validation 173
Contact Us 174
Disclaimer 174

List of Tables
Number of Products under Development for Diabetic Macular Edema, H1 2015 12
Number of Products under Development for Diabetic Macular Edema - Comparative Analysis, H1 2015 13
Number of Products under Development by Companies, H1 2015 15
Number of Products under Development by Companies, H1 2015 (Contd..1) 16
Number of Products under Development by Companies, H1 2015 (Contd..2) 17
Number of Products under Investigation by Universities/Institutes, H1 2015 18
Comparative Analysis by Late Stage Development, H1 2015 19
Comparative Analysis by Clinical Stage Development, H1 2015 20
Comparative Analysis by Early Stage Development, H1 2015 21
Comparative Analysis by Unknown Stage Development, H1 2015 22
Products under Development by Companies, H1 2015 23
Products under Development by Companies, H1 2015 (Contd..1) 24
Products under Development by Companies, H1 2015 (Contd..2) 25
Products under Investigation by Universities/Institutes, H1 2015 26
Diabetic Macular Edema - Pipeline by ActiveSite Pharmaceuticals, Inc., H1 2015 27
Diabetic Macular Edema - Pipeline by Acucela Inc., H1 2015 28
Diabetic Macular Edema - Pipeline by Aerpio Therapeutics, Inc., H1 2015 29
Diabetic Macular Edema - Pipeline by Alcon, Inc., H1 2015 30
Diabetic Macular Edema - Pipeline by Allergan, Inc., H1 2015 31
Diabetic Macular Edema - Pipeline by AlphaMab Co., Ltd, H1 2015 32
Diabetic Macular Edema - Pipeline by Ampio Pharmaceuticals, Inc., H1 2015 33
Diabetic Macular Edema - Pipeline by Astellas Pharma Inc., H1 2015 34
Diabetic Macular Edema - Pipeline by Auven Therapeutics Management L.L.L.P, H1 2015 35
Diabetic Macular Edema - Pipeline by Avalanche Biotechnologies, Inc., H1 2015 36
Diabetic Macular Edema - Pipeline by Eleven Biotherapeutics Inc., H1 2015 37
Diabetic Macular Edema - Pipeline by F. Hoffmann-La Roche Ltd., H1 2015 38
Diabetic Macular Edema - Pipeline by Foamix Pharmaceuticals Ltd., H1 2015 39
Diabetic Macular Edema - Pipeline by Gene Signal International SA, H1 2015 40
Diabetic Macular Edema - Pipeline by Genmab A/S, H1 2015 41
Diabetic Macular Edema - Pipeline by GlaxoSmithKline plc, H1 2015 42
Diabetic Macular Edema - Pipeline by Icon Bioscience, Inc., H1 2015 43
Diabetic Macular Edema - Pipeline by Kala Pharmaceuticals, Inc., H1 2015 44
Diabetic Macular Edema - Pipeline by Kowa Company, Ltd., H1 2015 45
Diabetic Macular Edema - Pipeline by Mabion SA, H1 2015 46
Diabetic Macular Edema - Pipeline by MacuCLEAR, Inc., H1 2015 47
Diabetic Macular Edema - Pipeline by Molecular Design International, Inc., H1 2015 48
Diabetic Macular Edema - Pipeline by NicOx S.A., H1 2015 49
Diabetic Macular Edema - Pipeline by Ohr Pharmaceutical Inc., H1 2015 50
Diabetic Macular Edema - Pipeline by Pfizer Inc., H1 2015 51
Diabetic Macular Edema - Pipeline by Quark Pharmaceuticals, Inc., H1 2015 52
Diabetic Macular Edema - Pipeline by Regeneron Pharmaceuticals, Inc., H1 2015 53
Diabetic Macular Edema - Pipeline by Santen Pharmaceutical Co., Ltd., H1 2015 54
Diabetic Macular Edema - Pipeline by SciFluor Life Sciences, LLC, H1 2015 55
Diabetic Macular Edema - Pipeline by Senju Pharmaceutical Co., Ltd., H1 2015 56
Diabetic Macular Edema - Pipeline by ThromboGenics NV, H1 2015 57
Assessment by Monotherapy Products, H1 2015 58
Number of Products by Stage and Target, H1 2015 60
Number of Products by Stage and Mechanism of Action, H1 2015 62
Number of Products by Stage and Route of Administration, H1 2015 64
Number of Products by Stage and Molecule Type, H1 2015 66
Diabetic Macular Edema Therapeutics - Recent Pipeline Updates, H1 2015 135
Diabetic Macular Edema - Dormant Projects, H1 2015 165
Diabetic Macular Edema - Dormant Projects (Contd..1), H1 2015 166
Diabetic Macular Edema - Discontinued Products, H1 2015 167